To hear about similar clinical trials, please enter your email below
Trial Title:
Soluble B7-H3 as a Biomarker for Osteosarcoma
NCT ID:
NCT05942456
Condition:
Biomarker
Progression
Osteosarcoma
Surveillance
Conditions: Official terms:
Osteosarcoma
Conditions: Keywords:
sB7-H3
osteosarcoma
biomarker
prognosis
clinical evaluation
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
ELISA: enzyme-linked immunosorbent assay
Description:
enzyme-linked immunosorbent assay
Arm group label:
sB7-H3 after neoadjuvant chemotherapy for osteosarcoma patients
Arm group label:
sB7-H3 of treatment-naive osteosarcoma patients
Summary:
Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3)
levels and unfavorable prognosis in patients with malignancies. However, the level of
sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present
study, we investigated whether sB7-H3 levels in serum could be as a biomarker for
osteosarcoma treatment.
Criteria for eligibility:
Study pop:
Initial treated osteosarcoma patients in PKUPH and later would recieve definitive surgery
in PKUPH with complete clinical materials.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- High Grade osteosarcoma verified with pathologic diagnosis.
- systemic treatment-naive before the first time Blood drawing.
- ECOG 0 or 1 and all the other imagings indicate that patients could tolerate
standard PKUPH-OS-02 protocol neoadjuvant chemotherapy.
- All radiographs are complete for clinical evaluation.
Exclusion Criteria:
- Patients who Can't tolerate blood drawing.
- Patients without complete medical records in PKUPH system.
- Patients who can't tolerate PKUPH-OS-02 neoadjuvant chemotherapy.
- other conditions that investigators think are not suitable for this study.
Gender:
All
Minimum age:
12 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Peking University People's Hospital
Address:
City:
Beijing
Zip:
100044
Country:
China
Status:
Recruiting
Contact:
Last name:
Lu Xie, M.D.
Phone:
+86-13401044719
Email:
xie.lu@hotmail.com
Start date:
June 5, 2023
Completion date:
December 31, 2024
Lead sponsor:
Agency:
Peking University People's Hospital
Agency class:
Other
Source:
Peking University People's Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05942456
